PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23619284-1	2013	Tandutinib is a novel inhibitor of tyrosine kinases FLT3, PDGFR and KIT.	tandutinib	0-10	platelet derived growth factor receptor beta	Homo sapiens	58-63	
16902153-1	2006	Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.	tandutinib	0-10	platelet derived growth factor receptor beta	Homo sapiens	145-184	
16902153-1	2006	Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.	tandutinib	0-10	platelet derived growth factor receptor beta	Homo sapiens	186-191	
16902153-1	2006	Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.	tandutinib	12-18	platelet derived growth factor receptor beta	Homo sapiens	145-184	
16902153-1	2006	Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT.	tandutinib	12-18	platelet derived growth factor receptor beta	Homo sapiens	186-191	
23047550-10	2012	The PDGFRbeta inhibitors gambogic acid, sunitinib, and tandutinib equally impaired the migration of meningioma cells.	tandutinib	55-65	platelet derived growth factor receptor beta	Homo sapiens	4-13	
23047550-13	2012	The inhibitory effect of gambogic acid and tandutinib against meningioma growth in vitro suggests that selective PDGFRbeta inhibitors, in combination with VEGF inhibitors, should be evaluated further as potential therapies for recurrent and malignant meningiomas.	tandutinib	43-53	platelet derived growth factor receptor beta	Homo sapiens	113-122	
21290244-2	2011	Phase II study of tandutinib was conducted to assess the effects of a continuously administered highly potent PDGFR inhibitor in this disease state.	tandutinib	18-28	platelet derived growth factor receptor beta	Homo sapiens	110-115	
21290244-10	2011	CONCLUSIONS: In vivo PDGFR inhibition with tandutinib correlated with accelerated disease progression.	tandutinib	43-53	platelet derived growth factor receptor beta	Homo sapiens	21-26	
18175263-3	2008	Millennium Pharmaceuticals Inc"s tandutinib (MLN-518) is an orally active inhibitor of FLT3 kinase and family members PDGFR beta and c-Kit.	tandutinib	33-43	platelet derived growth factor receptor beta	Homo sapiens	118-128	
18175263-3	2008	Millennium Pharmaceuticals Inc"s tandutinib (MLN-518) is an orally active inhibitor of FLT3 kinase and family members PDGFR beta and c-Kit.	tandutinib	45-52	platelet derived growth factor receptor beta	Homo sapiens	118-128